The table below shows Esperion Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$27.72M
-$22.63M
$53.83M
-$54.36M
-$38.99M
-$89.07M
Capital expenditure
$189.00K
$0.00
$73.00K
$0.00
-
$0.00
Investing cash flow
-$189.00K
$0.00
-$73.00K
$25.00M
-$18.10M
$0.00
Dividends paid
-
-
-
-
ESPR operating cash flow (10-K history)
Esperion Therapeutics, Inc. reported operating cash flow of -$13.09M for fiscal year 2025. That is up 44.6% from -$23.65M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$47.73M (FY 2016) to -$13.09M. Figures come from the company's audited annual reports as filed with the SEC.